Although this effect could exert a synergistic cytotoxic effect between chemotherapy and CD155 CAR-T cells on tumor cells, it may also increase the risk of on-target, off-tumor toxic effects due to increased CD155 expression on healthy cells. This evidence concerns the gene PVR and neoplasm.